Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Iontas Enters Licensing Agreement with Bristol Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Iontas Enters Licensing Agreement with Bristol Myers Squibb

Will establish the company’s mammalian display platform in its facilities.

By: Contract Pharma

Contract Pharma Staff

Iontas Limited, a biotechnology company focused on antibody discovery and technology development, has entered into a licensing agreement with Bristol Myers Squibb Company regarding the company’s proprietary mammalian display.
 
Under the terms of this agreement, Iontas will receive an upfront payment for accessing the technology platform and will work with Bristol Myers Squibb in establishing the platform within its facilities. Additional near-term payments include maintenance fees, the achievement of development milestones, and eventual royalty payments on all antibodies derived from the platform.

About the Technology

Iontas’ proprietary mammalian display technology enables large libraries of full-length antibodies to be expressed on the surface of mammalian cells, in a way that allows selection for optimal binding properties and optimal biophysical properties. These benefits can significantly reduce the risk of antibodies failing during the expensive manufacturing stages. Effectively, the platform allows the right lead antibodies to be selected early in the discovery process, reducing the requirement for any potential costly re-engineering to correct developability issues.
 
John McCafferty, chief scientific officer of Iontas and inventor of the platform, commented, “We are excited to have Bristol Myers Squibb, one of the global leading biopharmaceutical companies, as our licensing partner. Our mammalian display system not only allows the screening of tens of millions of clones directly for binding but also has a unique advantage to detect developability issues. This allows us to ’fix’ problematic antibodies and identify them during early drug discovery. This can save the industry significant time and money by generating developable products faster.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters